27 h. ago Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets FRANKFURT, Germany — Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions […]

Other

5 d. ago InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also received […]

Politics

5 d. ago Mission Success: Rocket Lab Deploys First Dedicated Launch for Japan Aerospace Exploration Agency (JAXA)

MAHIA, New Zealand, Dec. 13, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its first dedicated mission for the Japan Aerospace Exploration Agency (JAXA) – a pivotal marker of Electron’s global importance for regular, reliable, and dedicated […]

Society

7 d. ago Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, […]

Science

7 d. ago Treasury Secretary Bessent calls for looser regulations for the U.S. financial system

WASHINGTON (AP) — U.S. Treasury Secretary Scott Bessent is proposing to overhaul a regulatory panel that monitors the nation’s financial stability, by advocating for looser regulations. The Financial Stability Oversight Council, a U.S. body created in the wake of the 2008 global financial crisis, monitors risks to the financial system and coordinates regulators’ approaches to […]

Politics

8 d. ago Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation and mental distress1 Galderma’s phase II study builds on emerging research that reinforces the role of IL-31 – a neuroimmune cytokine that […]

Science

1 week ago Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT

– Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne – Study endpoints include safety and tolerability, effect on muscle force and function, and impact on muscle quality and regeneration – Enrollment of first study participant anticipated by end of 2025 TORONTO — Satellos Bioscience Inc. (TSX: MSCL, […]

Other

2 w. ago IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential […]

Other

2 w. ago Identity Becomes the Prime Target for Cybercriminals: Regula Highlights Five Incidents That Shaped 2025’s Threat Landscape

RESTON, Va., Dec. 03, 2025 (GLOBE NEWSWIRE) — Regula, a global developer of identity verification (IDV) solutions and forensic devices, has released an analysis of five major 2025 cyber incidents showing a clear shift: identity data — from ID photos and biometrics to login credentials — is becoming the main target for attackers. The cases — […]

Events

2 w. ago Fortuna Awards the Séguéla Mine Plant Expansion Study, Côte d’Ivoire

VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to announce that Lycopodium Minerals Canada Ltd. has been selected to undertake Séguéla’s Processing Plant Expansion Options Study (the “Study”), supporting Fortuna´s next phase of growth in Côte d’Ivoire. Key Highlights The Company recently reported: Fortuna Expands […]

Other

3 w. ago Nasdaq AxiomSL Expands RegTech Deployment with Revolut, Accelerating Global Growth

Integrated regulatory reporting and risk platform to support Revolut’s expanding global footprint LONDON and NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) — Nasdaq today announced a significant expansion of its strategic regulatory technology partnership with global fintech Revolut. The partnership centers on the deployment of Nasdaq AxiomSL, a regulatory reporting and risk platform used by […]

Other

3 w. ago Caledonia Mining Corporation Plc: Publication and Highlights of the Feasibility Study for Bilboes Gold Project

ST HELIER, Jersey, Nov. 25, 2025 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) is pleased to announce the decision to proceed with the Bilboes Gold Project (“Bilboes” or the “Project”) following completion and publication of the feasibility study (the “Feasibility Study”)1. Highlights Single-phase development confirmed […]

Other

3 w. ago Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab […]

Politics